# Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

> **NCT04946968** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 24 (actual)

## Conditions studied

- Advanced Solid Tumours
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Oral Dacomitinib

## Key facts

- **NCT ID:** NCT04946968
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-24
- **Primary completion:** 2027-04
- **Final completion:** 2027-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946968, "Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04946968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*